Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 19/20 | 0.86 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18173024 | 1.00 | KDM1A (0.86) | KDM1AMAOBMEN1ALDH1A1LMNA | |
| SCHEMBL18173020 | 1.00 | KDM1A (0.86) | KDM1AMAOBMEN1ALDH1A1LMNA | |
| SCHEMBL18172842 | 1.00 | KDM1A (0.86) | KDM1AMAOBMEN1ALDH1A1LMNA | |
| SCHEMBL18173026 | 1.00 | KDM1A (0.86) | KDM1AMAOBMEN1ALDH1A1LMNA | |
| SCHEMBL18173342 | 1.00 | KDM1A (0.86) | KDM1AMAOBMEN1ALDH1A1LMNA | |
| SCHEMBL18172847 | 1.00 | KDM1A (0.86) | KDM1AMAOBMEN1ALDH1A1LMNA | |
| SCHEMBL18172844 | 1.00 | KDM1A (0.86) | KDM1AMAOBMEN1ALDH1A1LMNA | |
| SCHEMBL18173017 | 1.00 | KDM1A (0.86) | KDM1AMAOBMEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL20527276 | 0.99 | KDM1A (0.84) | KDM1AMAOBMEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL20527428 | 0.99 | KDM1A (0.84) | KDM1AMAOBMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286172-B1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 241/4885MEN1 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.